West Pharmaceutical Services, Inc. WST SPXR3KPHARMA
Company Overview
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Why Investors Should Care
Generates a return on equity of 19.1%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 17.6%.
Maintains a net profit margin of 17.0%.
Carries low leverage with a debt-to-equity ratio of 0.11.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $3.07B (+6.3% YoY); net profit $493.70M.
- Trailing 12 Months Year-on-year growth — revenue +13.8%, earnings +18.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.1%, profit CAGR -5.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.12% |
| 1 Year: | 13.80% |
Compounded Profit Growth
| 5 Years: | -5.55% |
| 1 Year: | 18.10% |
Stock Price Performance
| 1 Year: | +38.51% |
| 6 Months: | +38.47% |
| 3 Months: | +8.17% |
| 1 Month: | -2.48% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)43.05 · Neutral
P/E of 43.53 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -5.5% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | WST West Pharmaceutical Services, Inc. SPXR3KPHARMA | 339.97 | 43.53 | $23.93B | 0.25% | 17.60% | 19.09% | 2.12% | -5.55% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 443.50M | 469.70M | 456.10M | 470.60M | 491.50M | 527.20M | 548.00M | 580.20M | 670.70M | 723.60M | 706.50M | 720.00M | 771.30M | 686.90M | 716.60M | 753.80M | 747.40M | 695.40M | 702.10M | 746.90M | - | - | 766.50M | 804.60M | 805.00M | 844.90M | 872.30M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 492.60M | 510.30M | 501.10M | 548.50M | 543.10M |
| Gross Profit | 109.90M | 109.70M | 118.20M | 108.30M | 123.30M | 133.30M | 121.10M | 134.20M | 125.00M | 125.10M | 134.40M | 142.20M | 135.60M | 146.80M | 157.90M | 147.80M | 153.20M | 167.00M | 195.10M | 194.60M | 211.10M | 271.90M | 315.10M | 288.20M | 284.60M | 321.50M | 268.00M | 271.30M | 291.40M | 288.30M | 230.20M | 230.00M | 264.70M | - | - | 273.90M | 294.30M | 303.90M | 296.40M | 329.20M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 104.30M | 115.00M | 119.80M | - | 115.30M | 137.30M |
| Operating Income | 44.00M | 47.80M | 39.10M | -3.50M | 30.00M | 61.20M | 51.30M | 60.50M | 42.00M | 62.90M | 53.40M | 60.30M | 60.80M | 70.70M | 80.50M | 67.30M | - | 88.00M | 103.60M | 99.20M | - | 175.60M | 211.30M | 181.40M | 189.70M | 228.40M | 186.20M | 155.30M | 182.50M | 177.30M | 122.80M | 126.20M | 161.30M | - | - | 158.90M | 174.50M | 175.10M | 181.10M | 191.90M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 198.50M | 215.10M | 208.30M | 227.20M | 228.90M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100.00K | 200.00K | -200.00K | 1.90M | 2.60M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 157.00M | 171.90M | 161.50M | 180.10M | 180.10M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.20M | 34.00M | 33.30M | 44.70M | 32.20M |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 55.40M | 66.10M | 56.30M | 63.90M | 74.30M | 91.20M | 82.30M | 98.40M | 151.20M | 187.30M | 175.60M | 173.80M | 188.50M | 120.60M | 140.00M | 155.10M | 161.30M | 115.30M | 111.30M | 136.00M | - | - | 131.80M | 140.00M | 132.10M | 138.80M | 154.00M |
| Diluted EPS | 0.43 | 0.45 | 0.38 | 0.02 | 0.30 | 0.60 | 0.50 | 0.81 | 0.51 | 0.67 | 0.58 | 0.75 | 0.73 | 0.73 | 0.88 | 0.75 | 0.84 | 0.99 | 1.21 | 1.09 | 1.29 | 1.99 | 2.47 | 2.31 | 2.29 | 2.48 | 1.59 | 1.85 | 2.06 | 2.14 | 1.55 | 1.51 | 1.85 | - | - | 1.82 | 1.92 | 1.82 | 1.92 | 2.15 |
| R&D Expense | 9.60M | 7.50M | 8.10M | 8.50M | 9.40M | 8.80M | 9.00M | 10.30M | 10.00M | 9.10M | 9.60M | 10.80M | 10.10M | 9.80M | 9.60M | 9.30M | - | 10.70M | 10.80M | 12.50M | - | 12.20M | 13.80M | 13.10M | 14.60M | 14.40M | 13.60M | 17.10M | 16.50M | 16.40M | 17.60M | 17.50M | 15.50M | - | 16.30M | 19.10M | 17.10M | - | 15.80M | 19.70M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.05B | 1.06B | 1.10B | 1.19B | 1.27B | 1.37B | 1.42B | 1.40B | 1.51B | 1.60B | 1.72B | 1.84B | 2.15B | - | 2.89B | 2.95B | 2.89B | 3.07B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.75B | 1.82B | 1.89B | 1.97B |
| Gross Profit | 302.60M | 303.60M | 318.10M | 339.30M | 387.70M | 434.70M | 447.80M | 455.80M | 501.40M | 512.90M | 545.40M | 605.70M | 767.80M | - | 1.14B | 1.13B | 998.50M | 1.10B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 375.40M | 421.80M | 407.60M | 467.90M |
| Operating Income | 124.10M | 97.50M | 90.70M | 109.60M | 135.10M | 162.40M | 182.00M | 128.60M | 195.20M | 225.80M | 240.30M | 296.60M | 406.90M | - | 760.80M | 707.40M | 590.90M | 636.10M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 808.40M | 844.30M | 743.90M | 772.80M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.90M | 9.00M | 3.00M | 500.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 679.90M | 698.00M | 585.50M | 600.90M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 114.70M | 122.30M | 107.50M | 121.60M |
| Net Income | 86.00M | 72.60M | 65.30M | - | - | - | - | - | - | - | 206.90M | 241.70M | 346.20M | - | 585.90M | 593.40M | 492.70M | 493.70M |
| Diluted EPS | 2.50 | 2.12 | 1.89 | 1.08 | 1.15 | 1.57 | 1.75 | 1.30 | 1.91 | 1.99 | 2.74 | 3.21 | 4.57 | - | 7.73 | 7.88 | 6.69 | 6.79 |
| R&D Expense | 18.70M | 19.90M | 23.90M | 29.10M | 33.20M | 37.90M | 37.30M | 34.10M | 36.80M | 39.10M | 40.30M | 38.90M | 46.90M | 52.80M | 58.50M | 68.40M | 69.10M | 74.30M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Sep 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.27B | 1.29B | - | 1.40B | 1.56B | 1.67B | 1.67B | 1.70B | 1.72B | 1.86B | 1.98B | 2.34B | 2.79B | - | 3.62B | 3.83B | 3.64B | 4.27B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.92B | 1.94B | 1.54B | 1.98B |
| Cash & Equivalents | 108.40M | 87.20M | 83.10M | 110.20M | 161.90M | 91.80M | 161.90M | 230.00M | 255.30M | 274.60M | 203.00M | 235.90M | 337.40M | 439.10M | 615.50M | - | 894.30M | 853.90M | 484.60M | 791.30M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 414.80M | 434.70M | 377.00M | 443.90M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 507.40M | 512.00M | 552.50M | 574.40M |
| Total Liabilities | - | - | 691.90M | 668.60M | - | 744.20M | 835.10M | 765.20M | 712.80M | 671.20M | 599.20M | 582.90M | 582.60M | 768.20M | 939.30M | - | 931.90M | 948.50M | 961.10M | 1.09B |
| Current Liabilities | - | - | 171.10M | 169.70M | - | 243.20M | 261.80M | 236.90M | 252.50M | 314.30M | 241.00M | 279.50M | 283.70M | 341.60M | 503.40M | - | 519.00M | 671.80M | 550.40M | 654.90M |
| Long Term Debt | - | - | 379.10M | 358.10M | - | 299.30M | 378.80M | 371.30M | 308.30M | 228.90M | 226.20M | 197.00M | 196.00M | 255.00M | 252.90M | - | 206.70M | 72.80M | 202.60M | 202.80M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 317.90M | 309.00M | 302.30M | 321.10M |
| Total Equity | 490.90M | 487.10M | 579.10M | 625.70M | - | 654.90M | 728.90M | 906.40M | 956.90M | 1.02B | 1.12B | 1.28B | 1.40B | 1.57B | 1.85B | - | 2.68B | 2.88B | 2.68B | 3.18B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 75.30M | 75.30M | 75.30M | 75.34M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 135.00M | 137.70M | 138.30M | 130.70M | 187.40M | 220.50M | 182.90M | 212.40M | 219.40M | 263.30M | 288.60M | 367.20M | 472.50M | - | 724.00M | 776.50M | 653.40M | 754.80M |
| Investing Cash Flow | -119.70M | -121.90M | -74.00M | -120.50M | -116.00M | -149.90M | -104.00M | -129.50M | -175.80M | -133.60M | -100.80M | -228.00M | -179.50M | - | -288.20M | -368.70M | -378.70M | -285.90M |
| Financing Cash Flow | -29.40M | -22.60M | -34.00M | -24.70M | -3.40M | -5.10M | -30.80M | -41.50M | -113.90M | -109.00M | -80.70M | -36.80M | -137.10M | - | -293.60M | -459.60M | -622.60M | -185.10M |
| Capital Expenditure | -138.60M | -104.90M | -71.10M | -95.40M | -131.30M | -151.90M | -111.90M | -131.60M | -170.20M | -130.80M | -104.70M | -126.40M | -174.40M | - | -284.60M | -362.00M | -377.00M | -285.90M |
| Free Cash Flow | -3.60M | 32.80M | 67.20M | 35.30M | 56.10M | 68.60M | 71.00M | 80.80M | 49.20M | 132.50M | 183.90M | 240.80M | 298.10M | - | 439.40M | 414.50M | 276.40M | 468.90M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 142.20M | -51.80M | -347.90M | 283.80M |
| Share Buybacks | 5.20M | 1.30M | 2.10M | 3.50M | 4.70M | - | 0 | 0 | 52.20M | 74.40M | 70.80M | 83.10M | 115.50M | 137.10M | 202.80M | 438.30M | 560.90M | 134.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 28.8% | 28.8% | 28.8% | 28.5% | 30.6% | 31.8% | 31.5% | 32.6% | 33.2% | 32.1% | 31.8% | 32.9% | 35.8% | - | 39.4% | 38.3% | 34.5% | 35.9% |
| Operating Margin % | 11.8% | 9.2% | 8.2% | 9.2% | 10.7% | 11.9% | 12.8% | 9.2% | 12.9% | 14.1% | 14.0% | 16.1% | 19.0% | - | 26.4% | 24.0% | 20.4% | 20.7% |
| Net Margin % | 8.2% | 6.9% | 5.9% | - | - | - | - | - | - | - | 12.0% | 13.1% | 16.1% | - | 20.3% | 20.1% | 17.0% | 16.1% |
| ROE % | 17.7% | 12.5% | 10.4% | - | - | - | - | - | - | - | 14.8% | 15.4% | 18.7% | - | 21.8% | 20.6% | 18.4% | 15.5% |
| ROCE % | - | 8.9% | 8.1% | 9.5% | 10.4% | 11.3% | 12.8% | 9.3% | 13.2% | 14.3% | 14.2% | 14.8% | 17.8% | - | 24.6% | 22.4% | 19.1% | 17.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.45% | 6.65M | $2.24B |
| 2 | Vanguard Capital Management LLC | 6.56% | 4.61M | $1.56B |
| 3 | Vanguard Portfolio Management LLC | 5.71% | 4.02M | $1.36B |
| 4 | FMR, LLC | 5.08% | 3.57M | $1.21B |
| 5 | State Street Corporation | 4.76% | 3.35M | $1.13B |
| 6 | Artisan Partners Limited Partnership | 3.43% | 2.41M | $813.91M |
| 7 | Bank Of New York Mellon Corporation | 2.90% | 2.04M | $689.73M |
| 8 | Generation Investment Management LLP | 2.88% | 2.03M | $684.50M |
| 9 | Geode Capital Management, LLC | 2.70% | 1.90M | $642.30M |
| 10 | T. Rowe Price Investment Management, Inc. | 2.56% | 1.81M | $609.14M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for WST
West Pharmaceutical Services (WST) And The GLP 1 Story Behind Its Fair Value Gap
How West Pharmaceutical Services stock has been performing West Pharmaceutical Services (WST) has drawn investor attention after recent share price moves, with the stock closing at US$339.97 on 3 September 2026. The company shows mixed retu…
Philips Expands Women's Health Ultrasound Portfolio With New Transducer
PHG broadens women's health ultrasound portfolio with the eV14-2v, offering enhanced imaging, a lighter design and remote collaboration.
Novocure Reports Patient Data Exposure in Cybersecurity Incident
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
Do You Believe West Pharmaceutical Services (WST) Represents a Tremendous Opportunity?
Generation Investment Management, an investment management firm, released its “Global Equity Strategy” second quarter 2026 investor letter. The letter can be downloaded here. The letter discusses the challenges of AI-driven market concentra…
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY's growth is driven by rising HSA assets and AI-led efficiencies, while cybersecurity risks remain a key concern.
WST — Frequently Asked Questions
What is the current share price of West Pharmaceutical Services, Inc. (WST)?
As of 2026-09-07 16:24 PDT, West Pharmaceutical Services, Inc. (WST) trades at $339.97 on NYSE. Its 52-week range is $230.63 to $365.50.
What is the market capitalisation of WST?
West Pharmaceutical Services, Inc. (WST) has a market capitalisation of $23.93B on NYSE.
What is the P/E ratio of WST?
WST trades at a trailing price-to-earnings (P/E) ratio of 43.53. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 8.34.
Does WST pay a dividend?
West Pharmaceutical Services, Inc. (WST) currently offers a dividend yield of 0.25%.
What is the return on equity (ROE) of WST?
WST has a return on equity (ROE) of 19.09%. Its return on capital employed (ROCE) is 17.60%.
Is WST a good stock to buy?
This page provides a data-driven analysis of West Pharmaceutical Services, Inc. (WST), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.